Andrew D. Badley

Enterprise Chair, Department of Molecular Medicine · Mayo Clinic

Credentials: · · ·

History

Impact of bcl2 Phosphorylation on Hiv Dynamics, Reservoir Size and Susceptibility to Venetoclax
National Institute of Allergy and Infectious Diseases · R56
Contact PI · $682.4K · Mayo Clinic Rochester
2024–2026
Prime Shock and Kill for HIV Erradication
National Institute of Allergy and Infectious Diseases · R01
Contact PI · $6.9M · Mayo Clinic Rochester
2014–2026
Evaluating the Role of the Novel Apoptosis Inhibitor TRAILshort, in Maintaining HIV Persistence
National Institute of Allergy and Infectious Diseases · R56
Contact PI · $606.9K · Mayo Clinic Rochester
2015–2023
Evaluating the Role of the Novel Apoptosis Inhibitor TRAILshort, in Maintaining HIV Persistence.
National Institute of Allergy and Infectious Diseases · R01
Contact PI · $2.5M · Mayo Clinic Rochester
2015–2021

Analytic Treatment Interruption (ATI) to Assess HIV Cure
Principal investigator · Enrolling by invitation
Mayo Clinic
2015–2035
Cardiopulmonary Bypass-Induced Lymphocytopenia and the Potential Effects of Protease Inhibitor
Principal investigator · Terminated · Phase 1
Mayo Clinic
2006–2008
The Effects of HIV Protease Inhibitors in Severe Sepsis
Principal investigator · Completed · Phase 1
Mayo Clinic
2003–2005
Study of Merimepodib in Combination With Remdesivir in Adult Patients With Advanced COVID-19
Study director · Terminated · Phase 2
ViralClear Pharmaceuticals, Inc.
2020